

press release

Novo Nordisk UK maintains consistent service and medicines supply throughout Covid-19 pandemic

Gatwick, 14 June 2021 – As the biggest insulin supplier in the UK, Novo Nordisk has continued to ensure that services and essential medicines reach patients across the UK, during the pandemic. As the situation evolves we are consistently replenishing our stock, and are working closely with the government, NHS England, industry bodies and charities to ensure that the supply of medicines will meet the needs of patients and the NHS on an ongoing basis.

In response to the pandemic we implemented a number of agile ways of working to support the NHS and deliver the high level of service that patients and healthcare professionals have come to expect from Novo Nordisk. This included:

- Investment in remote technology to support people living with diabetes, such as connective devices and digital insulin pens
- We funded and launched helplines for diabetes and haemophilia aimed at supporting patients and healthcare professionals, ensuring uninterrupted access to advice and support remotely
- We invested in technology to allow our teams to work virtually, reducing the risk of infection to both our employees, and to the NHS in instances where we come into contact with front-line services

We will continue to monitor the situation in the UK and globally, and have robust plans in place to ensure a strong continuation of supply as we move beyond the peak of this pandemic. We encourage healthcare professionals to continue to prescribe at a normal rate to allow us to maintain our stock levels and to distribute our medicines and treatments in an equitable fashion.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, “The healthcare industry has responded to this pandemic with exceptional agility, innovation and collaboration, not least with the ongoing development of new Covid-19 vaccinations. Our priority throughout has been our commitment to our patients and living up to a century of delivering life-changing medicines

to the UK. We are proud to be part of this industry and are confident that we can continue to maintain our services and supply of medicines as we move into this next phase.”

-ENDS-

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.co.uk

*Juliet Scott
Victoria Dacker*

*+44 7557490116
+44 7739358189*

*zjls@novonordisk.com
Victoria.Dacker@90ten.co.uk*